AMAG Pharmaceuticals Company Profile (NASDAQ:AMAG)

About AMAG Pharmaceuticals (AMAG)

AMAG Pharmaceuticals logoAMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AMAG
  • CUSIP: 00163U10
Key Metrics:
  • Previous Close: $24.50
  • 50 Day Moving Average: $22.83
  • 200 Day Moving Average: $26.51
  • 52-Week Range: $17.92 - $36.83
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 6.93
  • P/E Growth: -0.29
  • Market Cap: $844.74M
  • Outstanding Shares: 34,339,000
  • Beta: 1.09
  • Net Margins: 3.12%
  • Return on Equity: 11.10%
  • Return on Assets: 4.13%
  • Debt-to-Equity Ratio: 0.99%
  • Current Ratio: 2.24%
  • Quick Ratio: 2.12%

Analyst Ratings

Consensus Ratings for AMAG Pharmaceuticals (NASDAQ:AMAG) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.10)
Consensus Price Target: $32.75 (33.13% upside)

Analysts' Ratings History for AMAG Pharmaceuticals (NASDAQ:AMAG)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/20/2017Jefferies Group LLCSet Price TargetBuy$40.00MediumView Rating Details
3/6/2017Cantor FitzgeraldBoost Price TargetNeutral$24.00 -> $25.00N/AView Rating Details
2/3/2017Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
2/2/2017GuggenheimLower Price TargetBuy$42.00 -> $28.00N/AView Rating Details
1/31/2017JPMorgan Chase & Co.Set Price TargetHold$24.00N/AView Rating Details
1/11/2017Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
1/10/2017Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
1/10/2017Leerink SwannDowngradeOutperform -> Market Perform$39.00 -> $25.00N/AView Rating Details
1/9/2017Raymond James Financial, Inc.Reiterated RatingMarket Perform -> UnderperformN/AView Rating Details
5/9/2016Deutsche Bank AGLower Price TargetHold$42.00 -> $35.00N/AView Rating Details
3/28/2016Robert W. BairdLower Price TargetOutperform$26.00 -> $25.00N/AView Rating Details
3/28/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralN/AView Rating Details
1/28/2016Northland SecuritiesInitiated CoverageOutperform$40.00N/AView Rating Details
1/21/2016Barclays PLCInitiated CoverageEqual Weight$32.00N/AView Rating Details
(Data available from 4/28/2015 forward)


Earnings History for AMAG Pharmaceuticals (NASDAQ:AMAG)
Earnings by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
Earnings History by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2017Q416$0.24($0.31)$155.12 million$151.60 millionViewListenView Earnings Details
11/3/2016Q316$1.50$1.78$141.65 million$143.80 millionViewListenView Earnings Details
8/9/2016Q216$1.20$1.45$128.52 million$127.40 millionViewListenView Earnings Details
5/3/2016Q116$1.11$0.94$124.83 million$117.60 millionViewListenView Earnings Details
2/17/2016Q415$1.16$1.12$120.13 million$108.70 millionViewListenView Earnings Details
11/3/2015Q315$1.21($0.62)$113.88 million$103.50 millionViewListenView Earnings Details
7/23/2015Q215$0.75$1.12$94.05 million$123.90 millionViewListenView Earnings Details
5/5/2015Q115$1.04$1.11$84.66 million$89.50 millionViewListenView Earnings Details
10/30/2014Q314($0.08)$0.06$26.30 million$25.50 millionViewListenView Earnings Details
7/29/2014Q214($0.09)($0.07)$23.40 million$24.80 millionViewListenView Earnings Details
4/24/2014Q1($0.07)($0.33)$22.73 million$20.80 millionViewListenView Earnings Details
2/6/2014Q4($0.10)($0.17)$21.01 million$21.70 millionViewListenView Earnings Details
10/17/2013Q313($0.12)($0.01)$20.37 million$21.60 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.17)($0.09)$18.51 million$19.60 millionViewListenView Earnings Details
4/23/2013Q1 2013($0.20)($0.18)$17.99 million$17.90 millionViewListenView Earnings Details
3/1/2013Q4 2012($0.06)($0.17)$22.54 million$21.14 millionViewN/AView Earnings Details
11/1/2012Q312($0.26)($0.19)$20.43 million$17.70 millionViewN/AView Earnings Details
7/26/2012($0.39)$0.16ViewN/AView Earnings Details
5/1/2012($0.63)($0.58)ViewN/AView Earnings Details
3/5/2012($1.09)($0.87)ViewN/AView Earnings Details
11/4/2011($0.98)($0.78)ViewN/AView Earnings Details
5/3/2011($0.99)($1.05)ViewN/AView Earnings Details
2/25/2011($1.04)($0.94)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)
2017 EPS Consensus Estimate: $0.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.05)($1.05)($1.05)
Q2 20171$0.58$0.58$0.58
Q3 20171$0.43$0.43$0.43
Q4 20171$0.57$0.57$0.57
(Data provided by Zacks Investment Research)


Dividend History for AMAG Pharmaceuticals (NASDAQ:AMAG)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for AMAG Pharmaceuticals (NASDAQ:AMAG)
Insider Ownership Percentage: 2.30%
Insider Trades by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
Insider Trades by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/20/2016Julie KropSVPSell4,938$24.80$122,462.40View SEC Filing  
11/10/2015John A FallonDirectorBuy3,230$31.20$100,776.00View SEC Filing  
10/1/2015William K HeidenCEOSell2,000$39.69$79,380.00View SEC Filing  
9/1/2015William K HeidenCEOSell2,000$61.19$122,380.00View SEC Filing  
7/15/2015William K HeidenCEOSell20,000$75.00$1,500,000.00View SEC Filing  
6/15/2015Scott A HolmesSVPSell7,580$66.63$505,055.40View SEC Filing  
6/5/2015William K HeidenCEOSell66,875$69.90$4,674,562.50View SEC Filing  
6/4/2015Frank E ThomasCOOSell20,000$69.47$1,389,400.00View SEC Filing  
6/3/2015Scott A HolmesSVPSell22,516$68.88$1,550,902.08View SEC Filing  
1/9/2015Adage Capital Partners Gp LlcMajor ShareholderSell1,250,000$46.49$58,112,500.00View SEC Filing  
1/9/2014Christopher WhiteInsiderSell4,000$22.37$89,480.00View SEC Filing  
1/7/2014Christopher WhiteInsiderSell5,000$23.90$119,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for AMAG Pharmaceuticals (NASDAQ:AMAG)
Latest Headlines for AMAG Pharmaceuticals (NASDAQ:AMAG)
DateHeadline logoJohn Tucker appointed as Chief Executive Officer of scPharmaceuticals - April 27 at 1:43 AM logoAMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance - GlobeNewswire (press release) - April 26 at 3:41 PM logoAMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference - Nasdaq - April 26 at 3:41 PM logoAMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference - April 26 at 3:41 PM logoAMAG Pharmaceuticals (AMAG) Earns Media Impact Rating of 0.49 - April 26 at 12:36 PM logoAMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance - Yahoo Finance - April 25 at 3:27 PM logoAMAG Pharmaceuticals, Inc. (AMAG) Given Average Rating of "Hold" by Brokerages - April 25 at 9:56 AM logoAMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance - April 25 at 9:10 AM logoAMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AMAG-US : April 25, 2017 - April 25 at 9:10 AM logoAMAG Pharmaceuticals (AMAG) Given Media Impact Score of 0.08 - April 23 at 8:20 AM logoAMAG Pharmaceuticals, Inc. Expected to Post FY2019 Earnings of $0.68 Per Share (AMAG) - April 21 at 5:37 PM logoJefferies Group LLC Analysts Give AMAG Pharmaceuticals, Inc. (AMAG) a $40.00 Price Target - April 21 at 3:51 PM logoAMAG Pharmaceuticals (AMAG) Earns Daily Coverage Optimism Score of 0.31 - April 20 at 12:47 PM logoAMAG Pharmaceuticals to Host First Quarter 2017 Financial Results ... - GlobeNewswire (press release) - April 19 at 8:32 PM logoAMAG Pharmaceuticals to Host First Quarter 2017 Financial Results Conference Call and Webcast on Tuesday, May 2, 2017 at 8:00 a.m. ET - April 19 at 8:58 AM logoResearch Reports Initiation on Diagnostic Substances Stocks -- Palatin Technologies, AMAG Pharma, IDEXX Labs ... - PR Newswire (press release) - April 19 at 7:34 AM logoAMAG Files for FDA Approval of Subcutaneous Form of Makena - April 18 at 3:28 PM logoOMED Disappoints, PBYI Soars, AMAG Seeks Expanded Approval For Makena - Nasdaq - April 18 at 7:31 AM logoAMAG Pharmaceutical (AMAG) Submits Supplemental NDA to FDA for Makena® - - April 17 at 3:26 PM logoSomewhat Favorable Press Coverage Very Likely to Effect AMAG Pharmaceuticals (AMAG) Share Price - April 17 at 11:42 AM logoAMAG Pharmaceuticals, Inc. (AMAG) Expected to Post Quarterly Sales of $153.8 Million - April 15 at 8:15 AM logoSomewhat Critical Press Coverage Very Likely to Impact AMAG Pharmaceuticals (AMAG) Stock Price - April 14 at 3:58 PM logoAMAG Pharmaceuticals, Inc. (AMAG) Expected to Post Earnings of $0.09 Per Share - April 13 at 8:30 PM logoAMAG Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMAG) : April 12, 2017 - April 12 at 3:26 PM logoTherapeuticsMD Falls on Likely Delay in TX-004HR Approval - April 12 at 11:57 AM logoAMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AMAG-US : April 11, 2017 - April 11 at 3:30 PM logoAMAG Pharmaceuticals, Inc. (AMAG) Short Interest Update - April 8 at 10:22 PM logoAMAG Pharmaceuticals (AMAG) Presents At 16th Annual Needham Healthcare Conference - Slideshow - April 7 at 8:30 PM logoAMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement With Endoceutics for U.S. Rights to Intrarosa™ (Prasterone) - April 7 at 7:58 AM logoAMAG Pharmaceuticals stock surges 4% after closing $50 mln licensing agreement for menopause drug - April 7 at 7:58 AM logo15 companies with outsized sales growth and widening profit margins - April 7 at 7:58 AM featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals - March 31 at 3:36 PM logoAMAG Pharmaceuticals, Inc. (AMAG) Receives Consensus Recommendation of "Hold" from Analysts - March 31 at 2:06 PM logo5 Toxic Stocks to Get Rid Of or Play Short to Make Gains - March 30 at 3:53 PM logoAMAG Pharmaceuticals to Present at the Needham Healthcare Conference - GlobeNewswire (press release) - March 28 at 9:19 AM logoAMAG Pharmaceuticals to Present at the Needham Healthcare Conference - March 28 at 8:40 AM logoHealthcare Stocks on Investors' Radar -- Delcath Systems, Palatin Technologies, AMAG Pharma, and IDEXX ... - PR Newswire (press release) - March 14 at 8:02 AM logoAMAG Pharmaceuticals (AMAG) Presents At The Raymond James 38th Annual Institutional Investors Conference 2017 - March 8 at 8:34 PM logoAMAG Announces Management Changes and New Commercial ... - GlobeNewswire (press release) - March 7 at 8:33 PM logoAMAG Pharma (AMAG) Says COO Frank Thomas to Depart - - March 7 at 6:43 AM logoAMAG PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Fi - March 6 at 11:13 AM logoAMAG Pharmaceuticals to Present at Upcoming Investor Conferences - March 1 at 8:11 AM logoAMAG Pharma (AMAG), Palatin (PTN) Announce Rekynda Data Presentations at ISSWSH Meeting - - February 27 at 3:38 PM logo8:05 am AMAG Pharma and Palatin Technologies (PTN) presents additional results from the Phase 3 RECONNECT Studies (301, 302) of Rekynda at the ISSWSH Annual Meeting - February 27 at 3:38 PM logoAMAG PHARMACEUTICALS INC. Financials - February 24 at 3:41 PM logoAMAG Pharmaceuticals, Inc. -- Moody's revises outlook on AMAG to stable, affirms B2 CFR - February 22 at 11:33 AM logoAMAG PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report - February 21 at 7:16 AM logoAMAG Pharmaceuticals Inks $60M Drug Deal - February 16 at 3:33 PM logoAMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates - February 16 at 8:24 AM logoEdited Transcript of AMAG earnings conference call or presentation 14-Feb-17 1:00pm GMT - February 15 at 2:08 AM


Frequently Asked Questions for AMAG Pharmaceuticals (NASDAQ:AMAG)

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) posted its quarterly earnings results on Tuesday, February, 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by $0.55. The company earned $151.60 million during the quarter, compared to analyst estimates of $155.12 million. AMAG Pharmaceuticals had a net margin of 3.12% and a return on equity of 11.10%. AMAG Pharmaceuticals's revenue for the quarter was up 39.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.12 EPS.

When will AMAG Pharmaceuticals make its next earnings announcement?

AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.

Where is AMAG Pharmaceuticals' stock going? Where will AMAG Pharmaceuticals' stock price be in 2017?

10 brokerages have issued 12 month price objectives for AMAG Pharmaceuticals' shares. Their forecasts range from $24.00 to $45.00. On average, they expect AMAG Pharmaceuticals' share price to reach $32.75 in the next year.

What are analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:

  • 1. Jefferies Group LLC analysts commented, "No surprise vs. pre-announced 4Q16 results on 1/9/17. Another acquisition of women's health product Intrarosa also fails to excite investors (following Rekynda on 1/9/17). Given ongoing concerns, near-term we view limited upside; medium/long-term share price recovery would likely be driven by timely approval/successful launch of Makena 3.0 & strong Intrarosa uptake providing confidence in its commercial potential, which may not be materialized until ~2018." (2/15/2017)
  • 2. Guggenheim analysts commented, "Despite near-term setbacks, we continue to believe patience will be rewarded for AMAG investors with a longer-term horizon. However we are lowering our price target to $28 from $42. Our PT reduction is driven by lowered expectations for Makena life cycle extension. We believe Makena Sub-Q will face a challenging reimbursement environment, if approved, given the pain and Cmax PK data released this morning and expect generics to capture the majority of the market from '18+. Longer term stock price appreciation could be driven by Feraheme label expansion, CBR durability, Business Development, and Rekynda keep us positive." (2/2/2017)
  • 3. Cantor Fitzgerald analysts commented, "Rekindling desire with Rekynda. On January 9, AMAG announced that it obtained a North American licensing from Palatin Technologies (PTN, not covered) for Rekynda to treat hypoactive sexual desire disorder (HSDD) in pre- menopausal women. Safety and efficacy were established in two Phase 3 clinical trials and AMAG expects to file an NDA in early 2018. HSDD market is large and lacking in effective treatments. AMAG believes the U.S. population of patients with HSDD is 15 million, 5.8 million of which are pre-menopausal. An estimated 800,000 women are being treated for HSDD and 2.2 million are diagnosed but not treated." (1/20/2017)
  • 4. According to Zacks Investment Research, "We are concerned about AMAG’s dependence on sales of Makena, which primarily drives the company’s top line. We are also concerned about the company’s iron replacement therapy, Feraheme, which faces patent challenge in the U.S. In addition, inclusion of a boxed warning in Feraheme’s label is concerning. Moreover, termination of the marketing agreement with Takeda is a major setback for the company. Stiff competition and generic threats remain a woe as well. Estimates are stable ahead the company’s Q4 release. The company has recorded an average negative earnings surprise over the four trailing quarters. However, AMAG’s shares have outperformed the Medical-Biomedical/Genetics industry in the past one year." (1/9/2017)

Are investors shorting AMAG Pharmaceuticals?

AMAG Pharmaceuticals saw a decrease in short interest during the month of March. As of March 15th, there was short interest totalling 6,459,311 shares, a decrease of 4.3% from the February 28th total of 6,748,614 shares. Based on an average daily volume of 904,543 shares, the short-interest ratio is currently 7.1 days.

Who owns AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (3.57%), Russell Investments Group Ltd. (1.68%), Clark Estates Inc. NY (0.35%), Bank of Montreal Can (0.19%), State of New Jersey Common Pension Fund D (0.19%) and Livforsakringsbolaget Skandia Omsesidigt (0.14%). Company insiders that own AMAG Pharmaceuticals stock include Frank E Thomas, John A Fallon, Julie Krop, Scott A Holmes and William K Heiden.

Who sold AMAG Pharmaceuticals stock? Who is selling AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including DUPONT CAPITAL MANAGEMENT Corp, Nationwide Fund Advisors, ProShare Advisors LLC, Capstone Asset Management Co. and Buckhead Capital Management LLC.

Who bought AMAG Pharmaceuticals stock? Who is buying AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Russell Investments Group Ltd., Bank of Montreal Can, Fox Run Management L.L.C., Hikari Power Ltd, Cornerstone Financial Partners LLC, Clark Estates Inc. NY and Creative Planning.

How do I buy AMAG Pharmaceuticals stock?

Shares of AMAG Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of AMAG Pharmaceuticals stock cost?

One share of AMAG Pharmaceuticals stock can currently be purchased for approximately $24.60.

AMAG Pharmaceuticals (AMAG) Chart for Friday, April, 28, 2017

This page was last updated on 4/28/2017 by Staff